 |
Cempra
Cempra, Inc. (Nasdaq: CEMP) is a clinical stage pharmaceutical company focused on developing well-differentiated antibiotics to treat bacterial infections in the hospital and community. Cempra’s lead program, Solithromycin, is a next generation macrolide currently in Phase 3 clinical trials for community acquired bacterial pneumonia and gonorrhea, both of which have become alarming resistant infections.
Key features for potential broad use: excellent oral bioavailability, high stability in solution, demonstrated activity against azithromycin-resistant strains in vivo and in vitro.
- Global Phase 3 community-acquired bacterial pneumonia (CABP) program: SOLITAIRE-Oral topline data expected 1Q15; SOLITAIRE-IV enrollment ongoing.
- SOLITAIRE-U Phase 3 trial in gonorrhea and chlamydia initiated 3Q14.
- Pediatric and biodefense development supported by up to $58.6 million Biomedical Advanced Research and Development Authority (BARDA) contract.
- Exclusive license and development agreement in Japan with Toyama Chemical Co. (FUJIFILM).
|
 |
UVO3
UVO3, Inc. has developed a unique patented technology that now allows for the safe application of Ozone, a highly effective and proven disinfectant and combined it with the proven benefits of UV Germicidal Irradiation and UltraHEPA Air Microfiltration to help in the fight to reduce and control the rate of Healthcare Associated Infections.
Infection Control Professionals, Healthcare Workers and Financial Managers now have available a NEW COST EFFECTIVE ALTERNATIVE for complete room decontamination. The Infection Fighter® outperforms conventional methods for disinfecting hard surfaces, soft furnishings and airborne pathogens. |
